Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study

AbstractBackground: A better understanding of determinants for drug survival of anti-psoriatic agents may guide dermatologists in the right therapeutic choice.Objectives: To describe 2-year drug survival of conventional and biologic antipsoriatic treatments.Methods: SAHARA was a prospective study in patients with moderate-to severe psoriasis who initiated a conventional or biologic drug. Kaplan-Meier analysis estimated the drug survival and Cox-regression the predictors of treatment persistence at two years.Results: A total of 552 patients were included (conventional group n=181, biologic group n=371). After a median treatment duration of 21.4 months, the median time patients remained on methotrexate, etanercept and ustekinumab was not reached, whereas the median exposition time to cyclosporine, acitretin and adalimumab was 11.8, 10.6 and 25.5 months, respectively. There were 178 discontinuations for all causes, mainly in patients who initiated cyclosporine (58.3%), acitretin (52.8%), and adalimumab (46%)...